The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the drug than previously predicted.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare professionals and problems with the disclosure of transfers of value,

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes.